Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Paras Healthcare Limited operates eight multi-speciality hospitals across North India, with a focus on cardiac sciences, oncology and neurology. The company filed its DRHP with SEBI on July 31, 2024, and received approval on October 18, 2024, and refiled on June 4, 2026. The IPO will include a fresh issue of ₹500 crore and an offer for sale of ₹1,300 crore by existing shareholders. The DRHP highlights a number of business risks, such as patient volumes, demand for speciality services and competition from larger chains in the fast-growing organised healthcare sector. Total borrowings have increased and, along with revenue growth, have made debt management an ongoing focus area. Investors should refer to the DRHP and the public announcements made in this regard by the company or any other information available to the public.
An integrated healthcare provider in India, operating a network of multi-specialty hospitals across multiple states. The group offers a wide range of medical services, including cardiology, oncology, neurosciences, orthopaedics, organ transplantation, mother and child care, and critical care. Over the years, it has expanded its healthcare footprint by establishing hospitals in key cities and strengthening its presence in both metropolitan and tier-II markets.
Paras Healthcare Limited has filed its Draft Red Herring Prospectus (DRHP) with SEBI on July 31, 2024. SEBI approval was obtained by the company on 18 October 2024. The fresh DRHP was filed on June 4, 2026. The disclosure said the initial public offering (IPO) comprises a fresh issue and an offer for sale.
This article describes the company’s operations, financial position, industry standing and business risks from the DRHP and publicly available information.
The table below highlights the key details of the proposed public issue based on information available in the DRHP. Certain details such as the price band, lot size and issue dates are yet to be announced.
| Particulars | Details |
|---|---|
| IPO Type | Book Built Issue |
| IPO Open Date | To be announced |
| IPO Close Date | To be announced |
| Face Value | ₹1 per equity share |
| Price Band | To be announced |
| Lot Size | To be announced |
| Fresh Issue | Up to ₹500 crore |
| Offer for Sale | Up to ₹1,300 crore |
| Total Issue Size | Up to ₹1,800 crore |
| Listing Exchange | NSE and BSE |
This upcoming IPO comprises both a fresh issue and an offer for sale (OFS). The Fresh Issue is valued at up to ₹500 crore, with proceeds going to the company. The OFS covers up to ₹1,300 crore of shares sold by existing shareholders. This structure allows the company to raise fresh capital while giving existing shareholders an opportunity to partially divest their holdings.
Under SEBI's book-built norms, retail investors receive a 10% quota, qualified institutional buyers 75%, and non-institutional investors 15%. The final price band, issue dates, and lot size are yet to be announced.
Paras Healthcare Limited is a clinical speciality-led hospital platform that provides tertiary and quaternary healthcare services under the "Paras Health" brand. Established in 2006 with its first hospital in Gurugram, the company has expanded to a network of eight hospitals with an aggregate capacity of 2,211 beds across five states and one union territory—Haryana, Bihar, Uttar Pradesh, Rajasthan, Jharkhand, and Jammu and Kashmir.
Paras Healthcare runs multispecialty hospitals offering inpatient and outpatient care. The company has a focus on speciality services rather than general medicine alone. Its service portfolio includes cardiac sciences, oncology, and neurology.
As of March 31, 2026, the company operated eight hospitals across North India. These eight hospitals accounted for 66.07% of revenue from operations in FY2026 (Source: SEBI). The remaining revenue came from other sources within the broader healthcare portfolio.
Paras Healthcare earns revenue from hospital operations. This includes inpatient charges, outpatient fees, diagnostic services and speciality procedure charges. Cardiac sciences, oncology and neurology are the highest-revenue speciality services.
In FY2026, these three specialities contributed 74.70% of revenue from operations. In FY2025, they contributed 71.92%. In FY2024, they contributed 72.34% (Source: SEBI). This consistent contribution shows that speciality care drives the business model.
Paras Healthcare is among the leading multispecialty hospital chains focused on North India, a region that remains underserved compared to Southern and Western India in terms of hospital bed availability. The company runs a network of eight hospitals with a total of 2,211 beds, making it one of the leading private healthcare providers in its core markets. Its strategy is to expand to Tier 2 and Tier 3 cities where the demand for quality tertiary and quaternary care continues to outstrip supply.
India's private healthcare sector has grown as incomes rise and patient demand for quality care increases. Urban areas drive hospital demand because they have more income and a willingness to pay for speciality services. In many regions, the capacity of public healthcare is still limited, so there is room for private providers.
Organised healthcare growth drivers include:
Urban middle-class income and health expenditure on the rise
Growing population driving demand for chronic disease management
Speciality care becoming more accessible in tier 1 and metro cities
Medical technology progresses, allowing complicated treatment at private facilities
Insurance penetration rising, hospital care becoming affordable
Private hospital chains with established speciality services and multi-location networks can capture market share faster than standalone facilities.
This section gives an overview of the business growth, profitability and balance sheet position of Paras Healthcare Limited based on financial performance reported in the DRHP. The table below summarises the key financial parameters on a restated consolidated basis.
| Financials (₹ crore) | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Total Income | 1,628.78 | 1,314.21 | 1,151.02 |
| EBITDA | 335.58 | 156.46 | 154.41 |
| Profit After Tax | 43.83 | -57.98 | -15.33 |
| Total Assets | 2,071.14 | 1,810.45 | 1,477.66 |
| Net Worth | 394.94 | 280.49 | 338.51 |
| Total Borrowings | 854.10 | 727.93 | 547.53 |
Cardiac sciences, oncology and neurology together drive over 72% of revenue. These specialities command higher margins and attract referral networks.
Eight hospitals provide geographic diversification. Operating multiple facilities spreads fixed costs and builds brand presence across regions.
24% year-on-year growth from FY2025 to FY2026 shows market acceptance and operational scaling.
The swing from ₹57.98 crore loss in FY2025 to ₹43.83 crore profit in FY2026 signals operational efficiency improvements and cost management.
More than doubling of EBITDA from ₹156.46 crore to ₹335.58 crore shows improving core business performance.
Total borrowings at ₹854.10 crore were higher than ₹727.93 crore in FY2025. The company will have to be consistently profitable to service the debt.
Fixed costs such as salaries, rent and equipment maintenance are not significantly affected by patient volumes. Lower patient admissions directly affect profitability.
The risk of concentration from three specialities represents more than 72% of revenues. Any changes in competition or referral patterns in these areas would affect results.
Hospital operations are subject to ongoing regulatory requirements from health authorities, labour laws and safety standards.
National and regional chains with larger numbers of hospitals and greater name recognition compete for the same patient pool.
Good hospitals depend upon attracting and retaining experienced doctors and specialists. Talent turnover could affect service quality.
All eight hospitals are in North India. Any regional economic slowdown would affect the entire business at once.
Before evaluating the IPO, investors may consider the following factors:
The sustainability of 24% revenue growth and the drivers behind it
Reasons for the company's loss in FY2025 and whether the turnaround is sustainable
Debt levels and the trajectory of debt-to-equity ratios
Speciality service mix and any shifts in revenue contribution across cardiology, oncology and neurology.
Planned use of fresh issue proceeds and capital expenditure plans
Patient demographics and geographic spread across the eight hospitals
Bed occupancy rates and average revenue per bed across facilities
Medical professional retention and recruitment plans
Competition in North India's organised healthcare market
Insurance reimbursement trends and patient payment mix
Disclaimer :
Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading